CPC A61K 39/0283 (2013.01) [A61K 39/0258 (2013.01); A61K 39/104 (2013.01); A61K 39/105 (2013.01); A61K 39/385 (2013.01); C07K 14/195 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/6068 (2013.01); A61K 2039/6087 (2013.01); C07K 2319/034 (2013.01); Y02A 50/30 (2018.01)] | 7 Claims |
1. A bioconjugate vaccine comprising:
(i) a protein carrier, which is a modified, genetically detoxified Exotoxin of Pseudomonas aeruginosa (EPA), comprising at least two[[ ]] inserted consensus sequences, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline[[ ]]; and
(ii) at least one antigenic polysaccharide from at least one bacterium, N-linked to the protein carrier by attachment of the antigenic polysaccharide to the asparagine residue of the D/E-X-N-Z-S/T consensus sequence, wherein the at least one antigenic polysaccharide is a bacterial 0-antigen from one or more strain of Shigella, Escherichia coli (E. coli) or Pseudomonas aeruginosa; and,
optionally, an adjuvant.
|